Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs
Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries, according to a study to be reported at ESMO 2018 Congress.…
HER2+ Early Breast Cancers Where Shorter-Course Trastuzumab Could be an Option
Comparison of Available Treatment Strategies and Chemotherapeutic Options for Locally Advanced Head and Neck Cancer
Survivors of Childhood Extracranial Malignancy Who Received Chemotherapy Are Likely to Have Long-Term Neurological Toxicity
Patients with Advanced Lung Adenocarcinoma and Complex EGFR Mutations Demonstrate Different Response Rates to TKI Therapy
Dr Sandra Ortiz-Cuaran, who discussed the poster data, said that complex EGFR mutations account for 3.2% of the entire EGFR mutation spectrum. Patients with double classical mutations had the best PFS compared with other mutation types and may benefit more from TKIs treatment. Those who harboured complex mutations with classical pattern or double atypical mutations…
Further Evidence that Immunotherapy Provides a Longterm Survival Benefit for Lung Cancer Patients
Why Many Patients Join Phase 1 Clinical Trials
”Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France. “The importance of early stage trials is increasing because of the pressing need for new drugs,” said Dr Markus Joerger, Attending Medical…
Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology
Biosimilars Create Opportunities for Sustainable Cancer Care
Single-Arm Trials Improve Early Access to Rare Cancer Drugs
World Cancer Day 2016
On World Cancer Day, ESMO, the leading European professional organization for medical oncology, puts cancer patients center stage by organizing a workshop dedicated to exploring ways that advocacy networks can drive research. “Patients are the largest under-used resource of our health systems,” said Dr. Bettina Ryll, Sweden, Chair of the ESMO Patient Advocates Working Group. “They…